MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ
403.66
+7.62
+1.92%
Opening 15:34 12/19 EST
OPEN
399.11
PREV CLOSE
396.04
HIGH
408.14
LOW
396.06
VOLUME
1.18M
TURNOVER
--
52 WEEK HIGH
495.55
52 WEEK LOW
205.87
MARKET CAP
53.33B
P/E (TTM)
1765.02
1D
5D
1M
3M
1Y
5Y
1D
Noteworthy ETF Inflows: CGGR, TDG, ALNY, DHI
NASDAQ · 4h ago
PeptiDream Achieves Preclinical Milestone in siRNA Delivery Collaboration with Alnylam
Reuters · 1d ago
Harbor Long-Term Growers ETF Q3 Takeaways From Momentum In Artificial Intelligence
Seeking Alpha · 1d ago
Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today
Benzinga · 1d ago
Alnylam To Expand Massachusetts Manufacturing Facility With $250 Million Investment
NASDAQ · 2d ago
Alnylam to invest $250M to expand manufacturing facility in Massachusetts
TipRanks · 2d ago
Alnylam Pharma To Invest $250M To Advance siRNA Enzymatic-Ligation Manufacturing Facility
Benzinga · 2d ago
Alnylam Invests $250 Million to Expand RNAi Drug Manufacturing in Massachusetts
Reuters · 2d ago
More
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Webull offers Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ: ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.